首页> 外文期刊>Expert review of anti-infective therapy >Antibiotic-lock therapy for long-term catheter-related bacteremia: a review of the current evidence.
【24h】

Antibiotic-lock therapy for long-term catheter-related bacteremia: a review of the current evidence.

机译:抗生素锁定疗法用于长期导管相关菌血症:当前证据的综述。

获取原文
获取原文并翻译 | 示例
       

摘要

Catheter-related bloodstream infections (CRBSIs) are a major cause of morbidity and mortality, especially among patients receiving hemodialysis, parenteral nutrition and chemotherapy. Antibiotic-lock therapy (ALT) represents a promising technique in the modern treatment of CRBSIs. In this review, we attempt to clarify the potential role of ALT in the treatment of long-term catheter-related bacteremia, based on the available evidence from published studies reporting on this issue. We identified 28 articles that were considered appropriate to be included in our review, only three of which were comparative studies. There is some evidence that ALT administered concurrently with systemic therapy may represent a significant therapeutic approach for CRBSIs involving long-term catheters. Prolonged infection-free catheter survival in the reported series is suggestive of sterilization of the catheters by ALT. The only reported comparison shows better outcome with ALT than with catheter exchange. Immunodeficient states, such as HIV, and the use of totally implanted devices instead of tunneled catheters may predispose to CRBSI treatment failure. No serious adverse effects, such as emergence of resistance or increased infectious complications, were found to be associated with the use of ALT in the reviewed studies. However, more comparative studies should be performed to examine this important therapeutic issue further.
机译:导管相关的血流感染(CRBSI)是发病率和死亡率的主要原因,尤其是在接受血液透析,肠胃外营养和化学疗法的患者中。抗生素锁定疗法(ALT)在CRBSI的现代治疗中代表了一种有前途的技术。在这篇综述中,我们试图根据已发表的报告该问题的现有证据,阐明ALT在治疗长期导管相关菌血症中的潜在作用。我们确定了28篇认为适合纳入我们的评价的文章,其中只有三篇是比较研究。有证据表明,ALT与全身治疗同时给药可能代表了涉及长期导管的CRBSI的重要治疗方法。在所报道的系列中,无感染导管的生存期延长提示ALT对导管进行了灭菌。唯一报告的比较显示,ALT优于导管更换。免疫缺陷状态(例如HIV)以及使用完全植入的设备代替隧道导管可能导致CRBSI治疗失败。在回顾性研究中,没有发现严重不良反应如耐药性的出现或感染并发症的增加与使用ALT有关。但是,应该进行更多的比较研究以进一步检查这个重要的治疗问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号